ASCO 2024: J&J’s early radioligand prostate cancer trial reports four patient deaths
Nearly 37% of subjects experienced serious treatment-emergent adverse events, with thrombocytopenia and interstitial lung disease (ILD) being notable events.
Nearly 37% of subjects experienced serious treatment-emergent adverse events, with thrombocytopenia and interstitial lung disease (ILD) being notable events.
What's Your Reaction?
